Unicycive Therapeutics Faces Legal Action from Investors Over Securities Class Action
In a significant legal development, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently facing a securities class action suit, with a lead plaintiff deadline set for November 2, 2026. The lawsuit has been initiated by Levi & Korsinsky, LLP on behalf of investors who acquired securities between December 29, 2025, and June 29, 2026. Named in the action are the company’s Chief Executive Officer, Shalabh Gupta, and Chief Financial Officer, John Townsend, who are being charged under Section 20(a) control person claims. These allegations center on their failure to verify significant progress claimed by a third-party manufacturer toward compliance with FDA regulations.
The complaint details that the executives held the power to oversee Unicycive's SEC reports, press releases, and communications with analysts and investors. They are accused of having failed in their duty to ensure that the disclosures made to the market were accurate. On June 29, 2026, Unicycive’s stock closed at $7.70; however, after the company disclosed a second Complete Response Letter from the FDA, the stock plummeted to $4.69 the next day—a dramatic decline of 39.1% in a single session, driven by heavy trading volume.
The class action claims that Gupta and Townsend, due to their positions, were privy to material non-public information indicating that the company had not conducted necessary inspections or audits of the vendor's facility for current Good Manufacturing Practice (cGMP) compliance. The complaint asserts that by presenting the vendor's progress as verified when it was not, the executives misled investors, resulting in considerable financial losses.
As per the laws laid out by the Sarbanes-Oxley Act, officers who sign off on a company’s filings are personally accountable for ensuring no material facts are omitted. This places a significant burden on Gupta and Townsend, linking their responsibilities directly to the statements made in Unicycive's fiscal filings.
Joseph E. Levi, an attorney involved in the case, stated, “Officers who certify a company's filings take on personal responsibility for what those filings say and what they leave out.” This highlights the serious implications for the executives involved, as shareholders have the right to challenge the veracity of the disclosures made.
The internal dynamics of this case provide insights into the broader implications of corporate governance and executive accountability in publicly traded companies. The lawsuit underscores the significance of transparency in communications between corporations and their investors, particularly during crucial compliance processes with regulatory bodies like the FDA.
Levi & Korsinsky encourages eligible investors to consider filing a claim, emphasizing that even those who have sold their UNCY shares may still be able to seek recovery depending on the circumstances of their purchases and the subsequent losses incurred. The firm has a proven track record in advocating for shareholder rights, having recouped hundreds of millions of dollars for investors over the past two decades.
As the lead plaintiff deadline approaches, current and former investors are advised to review their brokerage records for details on their share purchases during the specified period. Those impacted and looking to participate in the class may submit their information for evaluation at no cost, as the case progresses through the legal system. It remains essential for shareholders to stay informed about their rights and any potential recovery options available to them in light of the unfolding legal proceedings against Unicycive Therapeutics.
The complaint details that the executives held the power to oversee Unicycive's SEC reports, press releases, and communications with analysts and investors. They are accused of having failed in their duty to ensure that the disclosures made to the market were accurate. On June 29, 2026, Unicycive’s stock closed at $7.70; however, after the company disclosed a second Complete Response Letter from the FDA, the stock plummeted to $4.69 the next day—a dramatic decline of 39.1% in a single session, driven by heavy trading volume.
The class action claims that Gupta and Townsend, due to their positions, were privy to material non-public information indicating that the company had not conducted necessary inspections or audits of the vendor's facility for current Good Manufacturing Practice (cGMP) compliance. The complaint asserts that by presenting the vendor's progress as verified when it was not, the executives misled investors, resulting in considerable financial losses.
As per the laws laid out by the Sarbanes-Oxley Act, officers who sign off on a company’s filings are personally accountable for ensuring no material facts are omitted. This places a significant burden on Gupta and Townsend, linking their responsibilities directly to the statements made in Unicycive's fiscal filings.
Joseph E. Levi, an attorney involved in the case, stated, “Officers who certify a company's filings take on personal responsibility for what those filings say and what they leave out.” This highlights the serious implications for the executives involved, as shareholders have the right to challenge the veracity of the disclosures made.
The internal dynamics of this case provide insights into the broader implications of corporate governance and executive accountability in publicly traded companies. The lawsuit underscores the significance of transparency in communications between corporations and their investors, particularly during crucial compliance processes with regulatory bodies like the FDA.
Levi & Korsinsky encourages eligible investors to consider filing a claim, emphasizing that even those who have sold their UNCY shares may still be able to seek recovery depending on the circumstances of their purchases and the subsequent losses incurred. The firm has a proven track record in advocating for shareholder rights, having recouped hundreds of millions of dollars for investors over the past two decades.
As the lead plaintiff deadline approaches, current and former investors are advised to review their brokerage records for details on their share purchases during the specified period. Those impacted and looking to participate in the class may submit their information for evaluation at no cost, as the case progresses through the legal system. It remains essential for shareholders to stay informed about their rights and any potential recovery options available to them in light of the unfolding legal proceedings against Unicycive Therapeutics.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.